Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

To develop a new therapeutic method targeting AKR1C1 for urothelial carcinoma micrometastasis

Funder: Japan Society for the Promotion of Science

Funding period
JPY 2.5 M
USD 22 K
Funding amount
Abstract
The effect of increasing bladder cancer cell cisplatin sensitivity and suppressing cell invasion capacity was observed in fenamic acid type nonsteroidal anti - inflammatory drugs such as flufenamic acid and mefenamic acid which have AKR1C1 inhibitory effect. In the study using clinical specimens, AKR1C1 was significantly increased in urothelial carcinoma metastatic site compared with primary site, and the effect of suppressing metastasis by the AKR1C1 inhibitor and enhancing the anticancer drug therapeutic effect on the metastatic lesion was expected. Currently, it is under observation that cisplatin and fenamic acid are administered to mice, and the application amount of fenamic acid is being studied.
Similar projects All >
Sorted by: Start Date
Project list item
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

National Cancer Institute to HIKMAT AL-AHMADIE

USD 821,670
2019 - 2024
Project list item
Defining the translational landscape of metastatic bladder cancer and its role in therapeutic response to chemotherapy

Bladder Cancer Advocacy Network to Brian Raymond Winters

USD 1,700
2017 - 2017
Project list item
[Targeting urothelial cancer by inhibiting drug transporter of tumor blood vessels] - Original in Japanese

Japan Society for the Promotion of Science to Nobuo SHINOHARA, Takahiro Osawa, Yasuhiro HIDA, Nako MAISHI

USD 41,281
2017 - 2020
Project list item
[p38 MAPK is involved in the development of resistance to chemotherapy in urothelial carcinoma] - Original in Japanese

Japan Society for the Promotion of Science to 俊輔 神明, Kazuhito NAKA, Tetsutaro Hayashi, Wataru YASUI, Jun TEISHIMA, Akio MATSUBARA

USD 42,460
2017 - 2020

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    5.1 Pharmaceuticals

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science